dxc014

DXC014 is a bispecific antibody-drug conjugate (ADC) designed for oncology use, targeting both **B7H3 (CD276)** and **prostate-specific membrane antigen (PSMA)** expressed on the surface of various solid tumor cells[3][7]. It utilizes a **topoisomerase I inhibitor** as its cytotoxic payload to induce tumor cell death[3][7]. Preclinical studies have demonstrated antitumor activity in models of solid tumors, and initial pharmacokinetic and safety investigations are ongoing[3][5][7][9]. DXC014 is being developed as a novel targeted therapy for advanced solid tumors, with the goal of exploiting dual antigen targeting to maximize tumor cell specificity and minimize off-target effects.